The Medical Imaging [MEDI] Scientific Review Group reviews proposals involving the application and validation of in vivo imaging of humans and animals, including early phase clinical studies of medical imaging systems, molecular probes and contrast agents, software, molecular imaging techniques, and related technologies. The underlying technologies may be refined and optimized during testing in response to research questions or clinical needs.
- Evaluation of improvements in technologies underlying medical imaging systems, as well as studies of available medical imaging systems to evaluate novel medical applications.
- Pre-clinical, Phase-I, and -II clinical trials of medical imaging systems and accessories, including MRI,MRS, optical, PET, PET/CT, fMRI, photoacoustic, DTI, nuclear medicine, ultrasound, multimodality, etc. and their associated contrast agents.
- Prediction, selection, and monitoring of therapeutic response based on imaging studies, with or without exogenous agents, using one or more modalities, especially for multi-temporal investigations to measure changes relative to a pretreatment baseline.
- Applications of imaging systems and modification of diagnostic methods for use in: screening; characterizing physiological effects,, and assessing risk.
- Image-guided interventions in integrated diagnostic and therapeutic systems.
- In vivo strategies and methods for characterizing tissue, and distinguishing between normal and pathologic states, based on estimates of biophysical, biomechanical, bioelectrical, biochemical, metabolic, perfusion/diffusion, or other properties.
- Development of surrogate endpoints based on quantitative imaging for use in clinical trials of medical devices, pharmaceuticals, biologics and other therapeutic interventions.
- Prediction, selection and monitoring therapeutic response by administering agents and imaging, to detect the location, amount, and fate of the agent in normal and diseased tissues.
- Diagnosis of functional disorders and classification of tissue as normal or pathologic based on exogenous agents that may be tailored to specific cellular processes or genetic expressions.